Biogen's Dapirolizumab Pegol Shows Promise in Reducing Lupus Flares and Steroid Dependence — Biogen Inc.

Event summary

Biogen and UCB presented data at EULAR 2026 showing dapirolizumab pegol (DZP) reduced flare rates and maintained disease control in SLE patients through Week 48.
Phase 3 PHOENYCS GO study results indicated DZP plus standard of care enabled glucocorticoid tapering to ≤7.5 mg/day in patients with baseline doses >7.5 mg/day.
Improvements in immunological markers, including reduced anti-dsDNA antibodies and increased complement proteins C3 and C4, were observed in patients treated with DZP.
The study also highlighted the importance of measuring patient-reported symptoms like fatigue in SLE clinical trials.

The big picture

The positive Phase 3 results for dapirolizumab pegol come at a time when the biotech industry is increasingly focused on developing targeted therapies for autoimmune diseases. The ability to reduce steroid dependence while maintaining disease control addresses a critical unmet need in SLE management, potentially positioning DZP as a key player in the competitive landscape of lupus treatments. The collaboration between Biogen and UCB underscores the strategic importance of partnerships in advancing complex therapeutic candidates through clinical development.

What we're watching

Regulatory Approval: Whether the Phase 3 data will be sufficient to secure regulatory approval for dapirolizumab pegol in SLE, given the stringent requirements for new treatments in autoimmune diseases.
Commercial Viability: The pace at which Biogen and UCB can bring dapirolizumab pegol to market and establish its position among existing and emerging therapies for SLE.
Long-term Efficacy: How sustained the benefits of dapirolizumab pegol will be beyond the 48-week study period, particularly in maintaining disease control and reducing long-term steroid exposure.